BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort
Open Access
- 23 January 2021
- Vol. 12 (2), 150
- https://doi.org/10.3390/genes12020150
Abstract
Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. We aimed to investigate the prevalence of BARD1 truncating variants in a cohort of patients with clinical suspicion of HBOC. A comprehensive BARD1 screening by multigene panel analysis was performed in 4015 unrelated patients according to our regional guidelines for genetic testing in hereditary cancer. In addition, 51,202 Genome Aggregation Database (gnomAD) non-Finnish, non-cancer European individuals were used as a control population. In our patient cohort, we identified 19 patients with heterozygous BARD1 truncating variants (0.47%), whereas the frequency observed in the gnomAD controls was 0.12%. We found a statistically significant association of truncating BARD1 variants with overall risk (odds ratio (OR) = 3.78; CI = 2.10–6.48; p = 1.16 × 10−5). This association remained significant in the hereditary breast cancer (HBC) group (OR = 4.18; CI = 2.10–7.70; p = 5.45 × 10−5). Furthermore, deleterious BARD1 variants were enriched among triple-negative BC patients (OR = 5.40; CI = 1.77–18.15; p = 0.001) compared to other BC subtypes. Our results support the role of BARD1 as a moderate penetrance BC predisposing gene and highlight a stronger association with triple-negative tumors.Funding Information
- Instituto de Salud Carlos III (PI19/00553; PI16/00563; PI16/01898; PI16/11363; PI15/00355; PI12/02585; SAF2015-68016-R)
- Government of Catalonia (2017SGR1282; 2017SGR496)
This publication has 41 references indexed in Scilit:
- Frequent incidence of BARD1‐truncating mutations in germline DNA from triple‐negative breast cancer patientsClinical Genetics, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast CancerJournal of Clinical Oncology, 2015
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panelCancer, 2014
- Cancer predisposing missense and protein truncatingBARD1mutations in non-BRCA1orBRCA2breast cancer familiesHuman Mutation, 2010
- Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional ConsequencesOnline Journal of Public Health Informatics, 2008
- Crystal Structure of the BARD1 BRCT Domains,Biochemistry, 2007
- BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinaseOncogene, 2005
- The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived MutationOnline Journal of Public Health Informatics, 2001
- Identification of a RING protein that can interact in vivo with the BRCA1 gene productNature Genetics, 1996